Skip to main content
. 2021 Feb 26;7(9):eabd8811. doi: 10.1126/sciadv.abd8811

Fig. 3. HDAC3 inhibition during acute phase promotes functional recovery after SCI.

Fig. 3

(A) Comparative IPA showing TFs predicted to be upstream regulators of the IAM gene programs at different activation stages. Genes denoted in blue (also marked by asterisks) are themselves differentially expressed between IAM and control microglia. (B) Interactome of HDAC3 with the top predicted upstream transcriptional regulators of IAM activation. (C) SCI functional recovery study with HDAC3 inhibitor (HDAC3i) RGFP966, comparing acute versus subacute treatment regimens as shown on top. Bottom: Locomotor recovery shown by the BMS scores (n = 3 mice for each condition). Two-way analysis of variance (ANOVA) with Bonferroni correction. **P = 0.002. ns, not significant.